Balestier
VC Fund
Balestier is a VC fund focused on Health Care and Medical Device. A Singaporean family fund.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Balestier invests in
Stages Balestier invests in
Countries Balestier invests in
Investment Focus
Industry
- Health Care 2 (67%)
- Medical Device 2 (67%)
- Wellness 1 (33%)
- Emergency Medicine 1 (33%)
Stage
- Series B 1 (33%)
- Series C 1 (33%)
- Series D 1 (33%)
Country
- France 1 (33%)
- United States 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
LimFlow SA
|
LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularizationefforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach. | $39.3M / Series D / Apr 05, 2022 | |
Cagent Vascular
|
Cagent Vascular is a medical device company developing minimally invasive technologies to treat cardiovascular disease. | $11.9M / Series B / Jul 12, 2018 | |
|
LimFlow SA
|
LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularizationefforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach. | $28.7M / Series C / Apr 16, 2018 |
Co-Investors
Sofinnova Partners
3 deals together
Bpifrance
2 deals together
Ben Franklin Technology Partners
1 deal together
Longitude Capital
1 deal together
Soleus Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Balestier invest in?
Balestier invests primarily in Health Care, Medical Device and Wellness startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Balestier last invest?
The most recent investment recorded for Balestier closed in Apr 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
